Lipei Shao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lipei Shao has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Robert P. Somerville
4 shared publicationsRongye Shi
4 shared publicationsDavid F. Stroncek
Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health , Bethesda, MD
3 shared publicationsMichaela Prochazkova
3 shared publicationsPing Jin
Center for Cellular Engineering, Clinical Center National Institutes of Health Bethesda Maryland USA
3 shared publications- David F. Stroncek
Department of Transfusion Medicine and Center for Cellular Engineering Clinical Center, National Institutes of Health Bethesda Maryland USA
2 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (4)
Transduction efficiency in clinical CAR T cell products: A retrospective study at a single center
- 2 September 2026
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (4)
Open AccessTransduction efficiency in clinical CAR T cell products: A retrospective study at a single center
- Open Access
- 17 March 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (5) , 1878-1884
A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome
Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurre...
- 17 March 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (5) , 1878-1884
Open AccessA multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome
Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurre...
- Open Access
- 1 June 2024
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 8 (6) , 404-414
T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function
T cell activation is an essential step in chimeric Ag receptor (CAR) T (CAR T) cell manufacturing and is accomplished by the addition of activator reagents that trigger the TCR and provide costimulation. We explore several T cell activation reagents and examine their effects on key attributes of CAR T cell cultures, such as activation/exhaustion markers, cell expansion, gene expression, and transduction efficiency. Four distinct activators were examined, all using anti-CD3 and anti-CD28, but incorporating different mechanisms of delivery: Dynabeads (magnetic microspheres), TransAct (polymeric nanomatrix), Cloudz (alginate hydrogel), and Microbubbles (lipid membrane containing perfluorocarbon gas). Clinical-grade lentiviral vector was used to transduce cells with a bivalent CD19/CD22 CAR, and cell counts and flow cytometry were used to monitor the cells throughout the culture. We observed differences in CD4/CD8 ratio when stimulating with the Cloudz activator, where there was a significant skewing toward CD8 T cells. The naive T cell subset expressing CD62L+CCR7+CD45RA+ was the highest in all donors when stimulating with Dynabeads, whereas effector/effector memory cells were highest when using the Cloudz. Functional assays demonstrated differences in killing of target cells and proinflammatory cytokine secretion, with the highest killing from the Cloudz-stimulated cells among all donors. This study demonstrates that the means by which these stimulatory Abs are presented to T cells contribute to the activation, resulting in differing effects on CAR T cell function. These studies highlight important differences in the final product that should be considered when manufacturing CAR T cells for patients in the clinic.
- 1 June 2024
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 8 (6) , 404-414
Open AccessT Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function
T cell activation is an essential step in chimeric Ag receptor (CAR) T (CAR T) cell manufacturing and is accomplished by the addition of activator reagents that trigger the TCR and provide costimulation. We explore several T cell activation reagents and examine their effects on key attributes of CAR T cell cultures, such as activation/exhaustion markers, cell expansion, gene expression, and transduction efficiency. Four distinct activators were examined, all using anti-CD3 and anti-CD28, but incorporating different mechanisms of delivery: Dynabeads (magnetic microspheres), TransAct (polymeric nanomatrix), Cloudz (alginate hydrogel), and Microbubbles (lipid membrane containing perfluorocarbon gas). Clinical-grade lentiviral vector was used to transduce cells with a bivalent CD19/CD22 CAR, and cell counts and flow cytometry were used to monitor the cells throughout the culture. We observed differences in CD4/CD8 ratio when stimulating with the Cloudz activator, where there was a significant skewing toward CD8 T cells. The naive T cell subset expressing CD62L+CCR7+CD45RA+ was the highest in all donors when stimulating with Dynabeads, whereas effector/effector memory cells were highest when using the Cloudz. Functional assays demonstrated differences in killing of target cells and proinflammatory cytokine secretion, with the highest killing from the Cloudz-stimulated cells among all donors. This study demonstrates that the means by which these stimulatory Abs are presented to T cells contribute to the activation, resulting in differing effects on CAR T cell function. These studies highlight important differences in the final product that should be considered when manufacturing CAR T cells for patients in the clinic.
- Open Access
- 12 March 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (7) , 757-768
CAR-T cell expansion platforms yield distinct T cell differentiation states
- 12 March 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (7) , 757-768
Open AccessCAR-T cell expansion platforms yield distinct T cell differentiation states
- Open Access
- 21 March 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (6) , 598-604
Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays
- 21 March 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (6) , 598-604
Open AccessReference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays